This allows for comprehensive therapy recommendations such as concomitant HER2/MET-amplifications as a potential primary resistance mechanism and MET and BRAF fusions that cannot be as easily assessed in the thoracic tumour board. This evidence concerns the gene ERBB2 and neoplasm.